3 recruiting, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 3, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow relmacabtagene autoleucel: new trials by email Literature Review of relmacabtagene autoleucel trials Research Report on relmacabtagene autoleucel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glofitamab Combined With CAR-T Therapy in R/R DLBCL Glofitamab, Obinutuzumab, Axicabtagene Ciloleucel - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 24 | 2026-03-01 | 2026-01-08 |
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor) - Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 30 | 2025-09-15 | 2026-01-21 |
| CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma Relma-cel - Non-Hodgkin Lymphoma, Large B-cell Lymphoma | Phase 2 | Recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 12 | 2024-08-15 | 2024-08-21 |
| CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors autologous stem-cell transplantation, Relmacabtagene autoleucel (relma-cel) - B-cell Non Hodgkin Lymphoma | Phase 2 | Recruiting | Ruijin Hospital | 16 | 2024-04-16 | 2026-01-06 |
| Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B | Phase 2 | Active not recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 46 | 2023-11-03 | 2025-02-11 |
| Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - B-cell Lymphoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 20 | 2023-01-03 | 2024-01-08 |
| Chidamide Bridging for CAR-T Therapy Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells - Non Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 120 | 2022-05-25 | 2024-03-06 |
Lymphoma, B-Cell (3) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1)
Ruijin Hospital (2) · Shanghai Ming Ju Biotechnology Co., Ltd. (2) · Chinese PLA General Hospital (1) · Peking University Cancer Hospital & Institute (1) · Sun Yat-sen University (1)
China (6)
Depei Wu, PhD (1) · Huilai Zhang (1) · Weidong Han, Ph.D (1) · Weili Zhao, PhD (1) · Yuqin Song, PhD (1)